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Background: Hepsin, (also called TMPRSS1) and TMPRSS3 are type II transmembrane serine proteases (TTSPs) that
are involved in cancer progression. TTSPs can remodel extracellular matrix (ECM) and, when dysregulated, promote
tumor progression and metastasis by inducing defects in basement membrane and ECM molecules. This study
investigated whether the gene and protein expression levels of these TTSPs were associated with breast cancer
characteristics or survival.
Methods: Immunohistochemical staining was used to evaluate hepsin levels in 372 breast cancer samples and
TMPRSS3 levels in 373 samples. TMPRSS1 mRNA expression was determined in 125 invasive and 16 benign breast
tumor samples, and TMPRSS3 mRNA expression was determined in 167 invasive and 23 benign breast tumor
samples. The gene and protein expression levels were analyzed for associations with breast cancer-specific survival
and clinicopathological parameters.
Results: Low TMPRSS1 and TMPRSS3 mRNA expression levels were independent prognostic factors for poor breast
cancer survival during the 20-year follow-up (TMPRSS1, P = 0.023; HR, 2.065; 95 % CI, 1.106–3.856; TMPRSS3, P = 0.013;
HR, 2.106; 95 % CI, 1.167–3.800). Low expression of the two genes at the mRNA and protein levels associated with
poorer survival compared to high levels (log rank P-values 0.015–0.042). Low TMPRSS1 mRNA expression was also
an independent marker of poor breast cancer prognosis in patients treated with radiotherapy (P = 0.034; HR, 2.344;
95 % CI, 1.065–5.160). Grade III tumors, large tumor size, and metastasis were associated with low mRNA and protein
expression levels.
Conclusions: The results suggest that the TTSPs hepsin and TMPRSS3 may have similar biological functions in the
molecular pathology of breast cancer. Low mRNA and protein expression levels of the studied TTSPs were
prognostic markers of poor survival in breast cancer.
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Globally, breast cancer is the most commonly diagnosed
cancer in women, while metastatic disease is the leading
cause of cancer-related deaths in this group [1]. Epithelial
integrity and intact extracellular matrix (ECM), which
includes basement membrane and interstitial connectivity* Correspondence: arto.mannermaa@uef.fi
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unless otherwise stated.tissue, are essential for normal cell behavior and tissue
homeostasis [2]. Remodeling and degradation of the ECM,
along with defects in structural cell-adhesion molecules,
play a significant role in breast cancer progression [3].
Type II transmembrane serine proteases (TTSPs) are a
relatively new subfamily of S1 class serine proteases in
humans comprised of 17 proteolytic enzymes [4, 5]. In
addition to their roles in normal tissue development and
homeostasis, TTSPs are also involved in several human
diseases, including cancer, and many show potential as
biomarkers of tumor progression and represent prospect-
ive therapeutic targets [6, 7]. TTSPs localize to the cellal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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intercellular and cell-ECM junctions. Accordingly, dysreg-
ulation of TTSPs is thought to be involved in the early
stages of tumorigenesis, tumor growth, and cancer cell
invasiveness that lead to metastasis [8, 9]. In this study, we
looked at the expression of two members of the TTSP
family, hepsin (also called TMPRSS1), which is encoded
by the TMPRSS1 gene, and TMPRSS3, encoded by the
TMPRSS3 gene.
Hepsin upregulation in malignant tumors has been
demonstrated in prostate and ovarian cancers as well as
in renal cell carcinoma [10–13]. A recent study used im-
munohistochemistry to show that hepsin protein levels
were upregulated in human breast cancer tumor samples
[14]. TMPRSS1 mRNA overexpression is associated with
ER(α)-positive human breast tumors [15], while TMPRSS3
overexpression has been implicated in pancreatic and epi-
thelial ovarian cancers [16, 17]. Missense mutations in the
TMPRSS3 gene that lead to structural TMPRSS3 defects
are associated with hereditary deafness [18]. Both hepsin
and TMPRSS3 belong to the hepsin/TMPRSS subfamily
of TTSPs and share structural features [5, 6]. TTSPs are
anchored to the cell membrane via an N-terminal trans-
membrane domain. At the C-terminus, TTSPs have an
extracellular serine protease domain that is required for
their catalytic activity [4, 7]. Notably, several soluble forms
of TTSPs that retain catalytic activity have also been de-
tected [4, 9]. Hepsin and TMPRSS3 appear to be capable
of autocatalytic activation, suggesting that they play roles
as initiators of proteolytic cascades that lead to ECM
remodeling [19, 20]. Overexpressed hepsin activates pro-
teolytic pathways and also directly interferes with cell-cell
and cell-ECM adhesion molecules. Hepsin can activate
hepatocyte growth factor (HGF) and urokinase-type plas-
minogen activator- (uPA) mediated proteolytic pathways,
which results in ECM degradation [21–23]. Hepsin plays a
physiological role as it directly and specifically cleaves
laminin-332 (ln-332, previously termed laminin-5), an im-
portant ECM protein involved in maintaining the struc-
tural integrity of the basement membrane [24]. It was
shown recently that hepsin becomes mislocalized when
liver kinase B1 (lkb1) expression is lost and that overex-
pressed hepsin induces basement membrane degradation
in breast cancer [25].
This is the first study to examine TMPRSS3 gene
expression in a set of clinical breast cancer samples and
to investigate whether altered TMPRSS1 and TMPRSS3
gene expression has an impact on the clinical outcome
of breast cancer patients. Here, we analyzed the associa-
tions of mRNA and protein expression of these genes
with clinicopathological parameters and breast cancer-
specific survival. Recently, we reported that TMPRSS3
SNP rs3814903 associated with both breast cancer risk
and survival and SNP rs11203200 associated with breastcancer survival [26]. Furthermore, TMPRSS1 SNPs
rs12151195 and rs12461158 remained independent
prognostic factors of breast cancer survival [26]. Our
previous study showed that another member of the
TTSP family, matriptase (encoded by the ST14 gene),
is associated with breast cancer survival [27]. We also
showed that several TMPRSS6 (encoding matriptase-2)
variants are related to breast cancer prognosis and
matriptase-2 expression levels decrease with tumor
progression [28]. These previous findings prompted
us to investigate whether altered expression of hepsin
and TMPRSS3 might also have a role in the molecular
pathology of breast cancer. Although the physiological
substrates for TMPRSS3 remain unclear, it is possible that
the biological mechanisms that lead to ECM degradation
are similar to those of hepsin. When overexpressed in
breast cancer, hepsin and TMPRSS3 could promote can-
cer cell invasiveness via dysregulated proteolytic activity.
This results in defects in the basement membrane and in
uncontrolled ECM degradation. However, the expression
levels seem to decrease as tumor malignancy increases,
and low expression levels of these proteins are associated
with poor breast cancer survival as well as with the adju-
vant treatments the patients received.Methods
Patients
The patient samples used in this study were obtained from
the Kuopio Breast Cancer Project (KBCP) sample set,
which includes 497 potential breast cancer cases from the
Northern Savo region of Eastern Finland. The patients
were diagnosed at Kuopio University Hospital between
April 1990 and December 1995 [27, 29]. All the patients
are of Caucasian race. The KBCP, including this study,
was approved by the official Research Ethics Committee
of Hospital District of Northern Savo. Informed written
consents were obtained from all of the patients and this
study was carried out in compliance with the Declaration
of Helsinki. Patient follow-up status was last revised in
February 2011. Table 1 shows the clinicopathological char-
acteristics of the breast tumor cases in this study as well
as data on the adjuvant treatments the patients received.RNA extraction and cDNA synthesis
Human breast tumor tissue sample retrieval during sur-
gery, RNA extraction from the tumor samples and cDNA
synthesis were performed as described in Kauppinen et al.
[27]. The mirVana™ miRNA Isolation Kit (Life Technolo-
gies, Carlsbad, CA) was used to extract total RNA from
frozen tissue samples, and the High Capacity cDNA
Reverse Transcription Kit (Life Technologies) for cDNA
synthesis. RNA extraction and cDNA synthesis were per-
formed according to the manufacturer’s instructions.
Table 1 Clinicopathological charasteristics of the patients
Cases in TMPRSS1 Cases in TMPRSS3 Cases in TMPRSS1* Cases in TMPRSS3
mRNA expression mRNA expression protein expression protein expression
Clinical variable n % n % n % n %
Breast tumor samples
Malignant 125 88.7 167 87.9 372 100 373 100
Benign 16 11.3 23 12.1
Histological type
Ductal 89 63.2 118 62.1 236 63.5 237 63.5
Lobular 20 14.2 31 16.3 73 19.6 72 19.3
Other malignant 16 11.3 18 9.5 63 16.9 64 17.2
Benign 16 11.3 23 12.1
Age at diagnosis
< = 39 12 9.6 14 8.4 31 8.3 31 8.3
40–49 22 17.6 29 17.4 91 24.5 91 24.4
50–59 29 23.2 38 22.8 88 23.7 88 23.6
60–69 18 14.4 28 16.7 53 14.2 54 14.5
> = 70 44 35.2 58 34.7 109 29.3 109 29.2
Tumor grade
I 24 19.2 28 16.8 87 23.4 88 23.6
II 51 40.8 74 44.3 162 43.6 161 43.2
III 48 38.4 60 35.9 105 28.2 106 28.4
NA 2 1.6 5 3.0 18 4.8 18 4.8
Tumor size
T1 46 36.8 63 37.7 173 46.5 174 46.6
T2 64 51.2 84 50.3 160 43.0 160 42.9
T3 9 7.2 12 7.2 19 5.1 20 5.4
T4 6 4.8 8 4.8 15 4.0 15 4.0
NA 5 1.4 4 1.1
Nodal status
Negative 71 56.8 87 52.1 197 53.0 198 53.1
Positive 51 40.8 73 43.7 155 41.6 155 41.5
NA 3 2.4 7 4.2 20 5.4 20 5.4
Stage
I 34 27.2 42 25.1 121 32.5 122 32.7
II 74 59.2 97 58.1 184 49.5 184 49.3
III 10 8.0 14 8.4 32 8.6 32 8.6
IV 4 3.2 7 4.2 13 3.5 13 3.5
NA 3 2.4 7 4.2 22 5.9 22 5.9
ER status
Negative 40 32.0 50 29.9 82 22.0 83 22.2
Positive 83 66.4 111 66.5 270 72.6 270 72.4
NA 2 1.6 6 3.6 20 5.4 20 5.4
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Table 1 Clinicopathological charasteristics of the patients (Continued)
PR status
Negative 56 44.8 70 41.9 140 37.6 141 37.8
Positive 67 53.6 91 54.5 212 57.0 211 56.6
NA 2 1.6 6 3.6 20 5.4 21 5.6
HER2 status
Negative 99 79.2 130 77.8 299 80.4 299 80.2
Positive 19 15.2 24 14.4 46 12.3 46 12.3
NA 7 5.6 13 7.8 27 7.3 28 7.5
ER/PR/HER2 status
Triple-negative 24 19.2 29 17.4 42 11.3 43 11.5
Non-triple-negative 94 75.2 122 73.0 289 77.7 288 77.2
NA 7 5.6 16 9.6 41 11.0 42 11.3
Radiotherapy
Yes 66 52.8 84 50.3 205 55.1 208 55.8
No 59 47.2 83 49.7 167 44.9 165 44.2
Chemotherapy
Yes 18 14.4 26 15.6 69 18.5 69 18.5
No 107 85.6 141 84.4 303 81.5 304 81.5
Tamoxifen
Yes 23 18.4 31 18.6 62 16.7 62 16.6
No 102 81.6 136 81.4 310 83.3 311 83.4
Latest follow-up status
Alive 38 30.4 52 31.2 149 40.1 149 39.9
Died of breast cancer 42 33.6 56 33.5 112 30.1 113 30.3
Died of other reason 45 36.0 59 35.3 111 29.8 111 29.8
NA, data not avalaible; *hepsin
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Of the KBCP sample set, 125 invasive breast cancer
samples and 16 benign breast tumor samples were avail-
able for TMPRSS1 mRNA absolute quantification by
real-time PCR, and 167 invasive and 23 benign samples
were available for TMPRSS3 mRNA quantification. Taq-
Man Gene Expression Assays (Life Technologies) were
used according to the manufacturer’s instructions (assay
#Hs01056332_m1 for TMPRSS1 and #Hs00225161_m1
for TMPRSS3), and peptidylprolyl isomerase A (PPIA)
was used as an endogenous control [Human Cyc Pre-
Developed TaqMan Assay Reagents (20X), Life Techno-
logies] [30]. Brilliant III Ultra-Fast QPCR Master Mix
(Agilent Technologies, Santa Clara, CA) and Mx3000P
real-time PCR system with MxPro-Mx3000P v4.10 soft-
ware (Agilent Technologies) were used according to the
manufacturer’s instructions. The PCR thermal profile was
1 cycle at 95-°C for 3 min followed by 45-55 cycles at 95-°C
for 20 s plus 30 s at 60-°C. The assays for the studied gene
and the control were in the same reaction. Samples were
analyzed in triplicate in 96-well plates. The amount of
cDNA varied from 2-75 ng in a final volume of 20-μl, andeach plate included standard curves for sample quantifica-
tion using a serial dilution of cDNA that was synthesized
from 5 randomly-selected KBCP tumor samples. The rela-
tive mRNA expression values were calculated by dividing
the raw expression of the studied gene with the raw PPIA
expression in the sample.
Immunohistochemistry
For immunohistochemical staining, 372 invasive breast
cancer tumor samples were available for hepsin analysis
and 373 samples were available for TMPRSS3 analysis.
Immunohistochemical staining was performed on 4-μm
sections cut from the tissue microarray (TMA) blocks.
The TMA blocks were constructed with a custom-built
instrument (Beecher Instruments, Silver Spring, MD).
The sample diameter of the tissue core in the array
block was 1000 μm and three samples from tumor tissue
of each case were studied. After deparaffinization and re-
hydration, the sections for TMPRSS3 analysis were heated
in a microwave oven for 3 × 5 min in citrate buffer
(pH 6.0). The sections for hepsin analysis were not heated.
The slides were treated for 5 min with 5 % hydrogen
Pelkonen et al. BMC Cancer  (2015) 15:431 Page 5 of 15peroxide to block endogenous peroxidase, then incubated
for 35 min at room temperature in 1.5 % normal serum
diluted in PBS to block non-specific binding. The blocked
sections were incubated overnight at 4-°C with the rabbit
polyclonal primary antibody against hepsin (LS-C24203/
28374; LifeSpan BioSciences, Seattle, WA) at a dilu-
tion of 1:250 or with an antibody against TMPRSS3
(NBP1-19582; Novus Biologicals, Littleton, CO) at a dilu-
tion of 1:250. The slides were then incubated with a bio-
tinylated secondary antibody for 35 min and with an
avidin-biotin-peroxidase complex for 45 min [Vectastain
Elite ABC Kit (anti-rabbit IgG); Vector Laboratories,
Burlingame, CA]. Slides were rinsed with PBS after each
step of the immunostaining procedure. The color was de-
veloped using diaminobenzidine tetrahydrochloride (DAB;
Sigma, St. Louis, MO). The slides were counterstained
with Mayer's hematoxylin, washed, dehydrated, cleared,
and mounted with Depex (BDH, Poole, UK). For the nega-
tive controls, the primary antibody was omitted.
Three slides from each TMA block were examined in
triplicate by two researchers (BB, HA) under the supervi-
sion of a senior pathologist (YS). The immunoreactivity of
hepsin and TMPRSS3 in the cytoplasm of epithelial tumor
cells was analyzed, and the intensity and the extent of
staining were scored (0, negative; 1, weak; 2, moderate; 3,
intense; Fig. 1a-d). The three slides were evaluated separ-
ately by researchers and were re-evaluated when values
were inconsistent to achieve a consensus. The tumor sam-
ples were divided into low and high expression groups
according to the median value of immunohistochemical
staining scores.A B
C D
Fig. 1 Immunohistochemical staining of hepsin and TMPRSS3 in invasive d
cells: a, weak staining of hepsin (score of 1 for intensity); b, intense staining
d, intense staining of TMPRSS3 (score of 3). All panels, 400x magnificationStatistical analysis
Statistical analyses were performed using IBM SPSS Sta-
tistics 19 software (IBM Corporation, Armonk, NY). The
non-parametric Mann-Whitney U test and the Kruskal-
Wallis test were used to study differences in continuous
mRNA expression values according to different clinico-
pathological parameters. Fisher’s exact test was used to
study associations between protein expression and clini-
copathological parameters. The odds ratios (ORs) and
the 95 % confidence intervals (95 % CIs) were deter-
mined using logistic regression analysis to describe the
strength of statistically significant associations between
expression levels and clinicopathological characteristics.
The Kaplan-Meier method was used in univariate sur-
vival analyses. Multivariate Cox’s proportional hazards
analysis was carried out in a forward stepwise method to
estimate the hazard factors having an impact on breast
cancer-specific death and relapse. In addition to mRNA
and protein expressions, Cox regression analysis exam-
ined the following clinicopathological parameters: tumor
grade, nodal status, tumor size, estrogen receptor (ER) sta-
tus, progesterone receptor (PR) status, and tumor histo-
logic type. In addition, the adjuvant treatments were used
as variables in the analyses including the treatment data.
All statistical tests were two-sided, and a P value of 0.05
was considered statistically significant.
We used an online Kaplan-Meier survival analysis tool
to validate the value of TMPRSS1 and TMPRSS3 as prog-
nostic biomarkers in breast cancer (http://kmplot.com/
analysis/index.php?p=service&cancer=breast) [31]. The
Kaplan-Meier plotter uses gene expression data anductal breast cancer. Cytoplasmic immunostaining of epithelial tumor
of hepsin (score of 3); c, weak staining of TMPRSS3 (score of 1);
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are downloaded from GEO (Affymetrix microarrays
only), EGA and TCGA. The patient samples are divided
into two groups according to the median gene expression
value similar to our analysis method. The groups are then
compared by Kaplan-Meier plot and the hazard ratio with
95 % confidence intervals and log rank P values are calcu-
lated [31].
Results
Low mRNA expression and low protein expression are
associated with advanced breast cancer tumor malignancy
The results of quantitative real-time PCR and immunohis-
tochemical staining were analyzed for associations with
the clinicopathological parameters of each patient. Table 2
presents the statistical association results for TMPRSS1
and TMPRSS3 mRNA expression, and Additional file 1:
Table S1 presents the statistical association results for
hepsin and TMPRSS3 protein expression. TMPRSS1
and TMPRSS3 mRNA expression was high in well-
differentiated malignant breast tumors compared to
benign breast tumors (Table 2; Additional file 2: Figure
S1A-B). However, poorly differentiated tumors expressed
low mRNA levels of both genes (TMPRSS1: P = 0.000015Table 2 Significant clinical variables associated with TMPRSS1 and TM
TMPRSS1 expressiona
Clinical variable n (%) P Me
Tumor type 0.002
Benign 16 (11.3) 0.2
Malignant 125 (88.7) 0.9
Tumor grade 0.000015
I 24 (19.5) 0.000007b 2.0
II 51 (41.5) NSc 1.6
III 48 (39.0) 0.000004d 0.5
ER status 0.000003
Negative 40 (32.5) 0.4
Positive 83 (67.5) 1.6
PR status 0.001
Negative 56 (45.5) 0.5
Positive 67 (54.5) 1.5
HER2 status 0.001
Negative 99 (83.9) 1.1
Positive 19 (16.1) 0.3
ER/PR/HER2 status 0.001
Triple-negative 24 (20.3) 0.4
Non-triple-negative 94 (79.7) 1.1
IQR, Interquartile range; NS, Not significant
aMann-Whitney U test was used for subgroups of two variables and Kruskal-Wallis t
bP value for comparing mRNA expression in benign tumors versus grade I tumors
cP value for comparing mRNA expression in grade I tumors versus grade II tumors
dP value for comparing mRNA expression in grade I tumors versus grade III tumorsand TMPRSS3: P = 0.0002; Kruskal-Wallis test; Table 2;
Additional file 2: Figure S1A-B). Likewise, logistic re-
gression analysis showed that low hepsin expression
levels were associated with poorly differentiated tumors
(P = 0.00009; OR, 3.289; 95 % CI, 1.811-5.973; Additional
file 1: Table S1), as were low levels of TMPRSS3 protein
expression (P = 0.0000002; OR, 5.006; 95 % CI, 2.721-
9.209; Additional file 1: Table S1).
The results in Table 2 and Additional file 1: Table S1
show that mRNA and protein expression levels were
high in well-differentiated tumors and low in poorly differ-
entiated tumors. Furthermore, logistic regression analysis
showed that low hepsin and TMPRSS3 protein expression
levels were positively associated with advanced clinical
stages III and IV (hepsin: P = 0.005; OR, 2.757; 95 % CI,
1.354-5.611 and TMPRSS3: P = 0.028; OR, 2.176; 95 % CI,
1.086-4.361) and that low hepsin expression was positively
associated with larger tumor sizes (T3 and T4; P = 0.034;
OR, 2.266; 95 % CI, 1.065-4.82), which indicates more
extensive disease. The Mann-Whitney U test showed
that low TMPRSS1 and TMPRSS3 expression levels were
associated with ER-negative status, PR-negative status,
and HER2-positive status (Table 2). In addition, low
TMPRSS1 mRNA expression was associated with triple-PRSS3 mRNA expression
TMPRSS3 expressiona
dian / IQR n (%) P Median / IQR
NS
7 / 0.57 23 (12.1) 0.98 / 0.56
6 / 2.10 167 (87.9) 0.92 / 1.74
0.0002
3 / 2.74 28 (17.3) 0.016b 1.76 / 2.80
7 / 2.41 74 (45.7) NSc 1.29 / 2.03
5 / 0.88 60 (37.0) 0.0001d 0.55 / 0.84
0.0027
5 / 0.84 50 (31.1) 0.55 / 0.84
7 / 2.44 111 (68.9) 1.24 / 2.34
0.0076
9 / 1.39 70 (43.5) 0.67 / 1.21
3 / 2.57 91 (56.5) 1.32 / 2.41
0.017
2 / 2.25 130 (84.4) 1.08 / 2.46
5 / 0.75 24 (15.6) 0.58 / 0.89
NS
9 / 0.98 29 (19.2) 0.69 / 1.86
2 / 2.33 122 (80.8) 1.09 / 1.81
est for subgroups of several variables
Pelkonen et al. BMC Cancer  (2015) 15:431 Page 7 of 15negative tumors (Table 2). As shown by the logistic regres-
sion analysis, low hepsin protein expression associated
with positive nodal status, while low TMPRSS3 protein
expression with PR-negative status and triple-negative
tumors (Additional file 1: Table S1).
Low mRNA and protein expression levels predict poor
breast cancer survival
Statistical analysis of 20-year follow-up data revealed
that the mRNA and protein expression levels of the
studied genes had prognostic value for the breast cancer
patients in this study. The univariate Kaplan-Meier ana-
lysis showed that low mRNA expression of TMPRSS1
(log rank, P = 0.042; Fig. 2a) and TMPRSS3 (log rank,
P = 0.015; Fig. 2b) predicted poorer breast cancer-
specific survival compared to high expression, as did low
expression of the TMPRSS3 protein (log rank, P = 0.028;
Fig. 2d) during the 20-year follow-up period. Similarly,











P (Log rank) = 0.315
P (Log rank) = 0.035 (10-year follow-up)
A
C
Fig. 2 Kaplan-Meier survival analysis of the breast cancer patients accordin
high and low expression groups relative to the median expression values. E
b, TMPRSS3 mRNA (median follow-up time 9.54 years); c, hepsin protein (m
follow-up time 10.94 years)Fig. 2c) predicted poorer breast cancer-specific survival
during the 10-year follow-up period, yet was not signi-
ficant during the 20-year follow-up period (P = 0.315,
Fig. 2c).
In the multivariate Cox regression survival analysis, low
mRNA expression of TMPRSS1 (P = 0.023; HR, 2.065;
95 % CI, 1.106-3.856; Table 3; Fig. 3a) and TMPRSS3 (P =
0.013; HR, 2.106; 95 % CI, 1.167-3.800; Table 3; Fig. 3b)
remained independent factors for predicting poor breast
cancer survival. The clinicopathological parameters that
remained independent prognostic factors of poor survival
included positive nodal status and large tumor size (T3,
T4) when TMPRSS1 expression was studied in the mul-
tivariate survival analysis. In the multivariate survival
analysis of TMPRSS3 expression, ER-negative status and
lobular histology were independent prognostic factors in
addition to positive nodal status and large tumor size.
Positive nodal status and large tumor size were statistically










P (Log rank) = 0.028
B
D
g to mRNA and protein expression levels. Patients were divided into
xpression of a, TMPRSS1 mRNA (median follow-up time 9.84 years);
edian follow-up time 11.05 years); and d, TMPRSS3 protein (median
Table 3 Multivariate Cox regression analyses of clinicopathological variables, mRNA and protein expression levels, and breast cancer
survival
Variable B (SE) Wald RR (95 % CI) P
Multivariate survival analysis with TMPRSS1 mRNA expression
Nodal status
Negative Ref.
Positive 0.786 (0.339) 5.369 2.194 (1.129–4.265) 0.020
Tumor size
T1 Ref.
T2 0.678 (0.421) 2.597 1.970 (0.864–4.492) 0.107
T3, T4 1.385 (0.504) 7.563 3.997 (1.489–10.729) 0.006
TMPRSS1 mRNA expression*
Low 0.725 (0.318) 5.187 2.065 (1.106–3.856) 0.023
High Ref.
Multivariate survival analysis with TMPRSS3 mRNA expression
Nodal status
Negative Ref.
Positive 1.091 (0.320) 11.596 2.976 (1.589–5.575) 0.001
Tumor size
T1 Ref.
T2 0.317 (0.373) 0.769 1.386 (0.668–2.874) 0.380
T3, T4 1.256 (0.452) 7.720 3.511 (1.448–8.516) 0.005
TMPRSS3 mRNA expression*
Low 0.745 (0.301) 6.111 2.106 (1.167–3.800) 0.013
High Ref.
Histology
Ductal 0.472 (0.551) 0.734 1.603 (0.545–4.715) 0.391
Lobular 1.501 (0.589) 6.497 4.487 (1.415–14.231) 0.011
Medullary, others Ref.
ER status
Negative 0.628 (0.310) 4.109 1.873 (1.021–3.437) 0.043
Positive Ref.
Multivariate survival analysis with combined TMPRSS1-TMPRSS3 mRNA expression
Combined mRNA expression†




Positive 0.975 (0.360) 7.327 2.650 (1.309–5.368) 0.007
Tumor size
T1 Ref.
T2 0.481 (0.433) 1.233 1.617 (0.692–3.779) 0.267
T3, T4 1.281 (0.505) 6.427 3.600 (1.337–9.691) 0.011
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Table 3 Multivariate Cox regression analyses of clinicopathological variables, mRNA and protein expression levels, and breast cancer
survival (Continued)
Multivariate survival analysis with combined hepsin-TMPRSS3 protein expression
Nodal status
Negative Ref.
Positive 0.905 (0.227) 15.942 2.473 (1.586–3.857) 0.00007
Tumor size
T1 Ref.
T2 0.176 (0.235) 0.559 1.192 (0.752–1.888) 0.455
T3, T4 0.891 (0.321) 7.696 2.438 (1.299–4.576) 0.006
Histology
Ductal 0.255 (0.322) 0.628 1.291 (0.687–2.426) 0.428




II 0.711 (0.290) 6.025 2.036 (1.154–3.591) 0.014
III 0.532 (0.337) 2.493 1.702 (0.880–3.294) 0.114
Combined protein expression†
Low 0.432 (0.214) 4.087 1.541 (1.013–2.342) 0.043
Others Ref.
Note: Analyses included tumor grade, histology, tumor size, nodal status, ER and PR status
B (SE), B coefficient with standard error; HR (95 % CI), hazard ratio of breast cancer death with a 95 % confidence interval; Ref., reference category in the
multivariate analysis
*The relative median value of mRNA expression level was used in the analyses
†The ‘combined low group’ included all cases with low expression levels of both genes
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tween protein expression and breast cancer prognosis
could not be identified in the multivariate survival analysis
(data not shown).
Associations between relapse-free survival during the
20-year follow-up period and expression levels were
studied using univariate Kaplan-Meier analysis. Patients
with low levels of TMPRSS3 mRNA and low levels of
TMPRSS3 protein had more frequent relapses (TMPRSS3:
log rank, P = 0.009; Additional file 3: Figure S2A and
TMPRSS3: log rank, P = 0.003; Additional file 3: Figure
S2B). In the Cox regression multivariate analysis, both low
TMPRSS3 mRNA expression and low TMPRSS3 protein
expression remained independent factors that had an
effect on relapse occurrence (Additional file 3: Figure
S2C-D). When studied separately, the association of local
recurrence with expression levels was not as strong as the
association of distant recurrence with expression levels
(data not shown). During 20-year follow-up period, distant
metastasis occurred more frequently in patients with low
TMPRSS1 expression levels (Additional file 4: Figure S3A),
low TMPRSS3 expression levels (Additional file 4: Figure
S3B), and low TMPRSS3 protein expression levels
(Additional file 4: Figure S3C).Low TMPRSS1 mRNA expression is associated with poor
survival in patients treated with radiotherapy
Associations between the studied expression levels and
breast cancer-specific and overall survival according to
the adjuvant therapies given to the patients were ana-
lyzed using univariate Kaplan-Meier analysis and multi-
variate Cox regression survival analysis. Low TMPRSS1
mRNA expression was associated with both poor breast
cancer-specific survival (log rank, P = 0.030; Cox regres-
sion analysis, P = 0.034; HR, 2.344; 95 % CI, 1.065-5.160;
Fig. 4a) and poor overall survival (log rank, P = 0.006;
Cox regression analysis, P = 0.007; HR, 2.392; 95 % CI,
1.276-4.484; Fig. 4b) in patients who were treated with
radiotherapy. There were no significant survival differ-
ences according to the TMPRSS1 mRNA level in pa-
tients who did not receive radiotherapy. Furthermore,
the Kaplan-Meier estimates of patients who received
chemotherapy showed that low TMPRSS1 mRNA expres-
sion was associated with poor breast cancer-specific
survival (log rank, P = 0.028) and poor overall survival (log
rank, P = 0.028).
When the treatment data was included in the survival
analyses, low TMPRSS3 mRNA expression was associ-






HR, 2.065; 95% CI, 1.106-3.856
P = 0.023
B (SE) = 0.725 (0.318)
Combined
low expression





B (SE) = 0.909 (0.325)




low expression (n = 100)
HR, 1.541; 95% CI, 1.013-2.342
P = 0.043









HR, 2.106; 95% CI, 1.167-3-800
P = 0.013
B (SE) = 0.745 (0.301)
Fig. 3 Cox regression multivariate analysis of breast cancer survival. Patients were divided into high and low expression groups relative to the
median expression values (a, b). Cox regression analysis of survival according to the expression of (a), TMPRSS1 mRNA (median follow-up time
9.79 years); b, TMPRSS3 mRNA (median follow-up time 9.51 years); c, TMPRSS1 and TMPRSS3 mRNA (median follow-up time 9.79 years); and d, hepsin
and TMPRSS3 protein expression (median follow-up time 11.05 years). In addition to expression levels, tumor grade, nodal status, tumor size, hormone
receptor status, and histologic type were included in the multivariate analyses. Positive nodal status and large tumor size (T3, T4) were other parameters
that were significantly associated with poorer breast cancer survival in the multivariate analyses
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independent factor predicting more frequent relapse
occurrence (log rank, P = 0.023; Cox regression analysis,
P = 0.021; HR, 1.831; 95 % CI, 1.094–3.063). Low TMPRSS3
protein expression also predicted poorer relapse-free
survival (log rank, P = 0.011; Cox regression, P = 0.031;
HR, 1.520; 95 % CI, 1.040–2.221) compared with high
TMPRSS3 expression. No significant results were found
between different treatment groups regarding TMPRSS3
expression.
The combination of low TMPRSS1-TMPRSS3 mRNA and
hepsin-TMPRSS3 protein expression predicts poor breast
cancer survival
The statistical associations between mRNA and protein
expression levels were assessed using Spearman rankcorrelation coefficient. TMPRSS1 expression levels cor-
related with hepsin protein expression levels (r = 0.18;
P = 0.05; n = 112), and TMPRSS3 expression levels cor-
related with TMPRSS3 protein expression levels (r = 0.24;
P = 0.04; n = 147). Positive correlations were also found
between TMPRSS1 and TMPRSS3 mRNA expression
(r = 0.39; P = 0.000007; n = 123) and between hepsin and
TMPRSS3 protein expression (r = 0.27; P = 0.0000001;
n = 371). Consequently, combined TMPRSS1 and TMPRSS3
mRNA expression and combined hepsin and TMPRSS3
protein expression were tested for statistical association
with clinicopathological parameters and breast cancer-
specific survival. The combination variables were formed
so that the breast cancer cases that expressed low mRNA
levels of both of the studied genes formed the ‘low com-
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Fig. 4 Low TMPRSS1 mRNA expression is associated with poor survival in patients treated with radiotherapy in Cox regression multivariate analysis.
Cox regression analysis of a, breast cancer-specific survival and b, overall survival according to the TMPRSS1 mRNA expression in patients treated with
radiotherapy. Adjustments were made for age, stage, grade, histologic type, hormone receptor status, hormonal treatment, and chemotherapy
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was used to forming a ‘low protein expression’ group.
Breast cancer cases with low combined expression
were associated with clinicopathological parameters that
indicate advanced tumor malignancy (Additional file 5:
Table S2).
Univariate Kaplan-Meier survival analyses showed that
low levels of both mRNA (log rank, P = 0.013; Additional
file 6: Figure S4A) and protein expression (log rank, P =
0.001; Additional file 6: Figure S4B) indicated poorer
breast cancer prognosis, with low expression levels associ-
ated with poor breast cancer survival and distant re-
currence during the 20-year follow-up period (Additional
file 6: Figure S4C-D). Both low mRNA (P = 0.005; HR,
2.482; 95 % CI, 1.312–4.698; Table 3; Fig. 3c) and low
protein expression (P = 0.043; HR, 1.541; 95 % CI, 1.013-
2.342; Table 3; Fig. 3d) remained independent factors for
survival in the multivariate Cox regression analysis, as did
positive nodal status and large tumor size (data not
shown). Taken together, these results indicate that the
protein expression levels of hepsin and TMPRSS3 correl-
ate with the mRNA levels of TMPRSS1 and TMPRSS3,
respectively. Further, low expression levels of TMPRSS1
and TMPRSS3 mRNA and hepsin and TMPRSS3 predict
advanced tumor malignancy and poorer prognosis.
The prognostic value of low TMPRSS1 and TMPRSS3
mRNA expression levels in breast cancer was validated in
a public gene expression dataset
The results obtained from the online Kaplan-Meier plotter
analysis tool presented that both low TMPRSS1 and
TMPRSS3 expression were significantly associated with
poorer relapse-free survival (TMPRSS1: log rank, P = 0;
HR, 0.61; 95 % CI, 0.55–0.69; n = 3554; Additional file 7:Figure S5A and TMPRSS3: log rank, P = 3.8e-10; HR, 0.66;
95 % CI, 0.58–0.73; n = 3554; Additional file 7: Figure
S5B), overall survival (TMPRSS1: log rank, P = 0.0083; HR,
0.73; 95 % CI, 0.57–0.92; n = 1117; Additional file 7: Figure
S5C and TMPRSS3: log rank, P = 0.00005; HR, 0.58; 95 %
CI, 0.46–0.74; n = 1117; Additional file 7: Figure S5D),
and distant metastasis-free survival in breast cancer
(TMPRSS1: log rank, P = 0.000099; HR, 0.67; 95 % CI,
0.55–0.82; n = 1609; Additional file 7: Figure S5E and
TMPRSS3: log rank, P = 0.0000039; HR, 0.62; 95 % CI,
0.51–0.76; n = 1609; Additional file 7: Figure S5F).
Discussion
This is the first study to link altered TMPRSS3 expres-
sion to breast cancer tumor progression and to show
that low TMPRSS1 and TMPRSS3 expression, both at
the mRNA and protein levels, has prognostic value for
poorer survival of breast cancer patients. Importantly,
this is also the first cancer study to show that altered
TMPRSS3 expression has prognostic value for cancer-
related death. In benign breast tumor cells, the expres-
sion levels of TMPRSS1 and TMPRSS3 are consistently
low, whereas the expression levels are higher in cancer
cells. In malignant samples, there was clearly a high de-
gree of intertumor variation in the expression levels of
the studied genes. However, our results indicated that
despite overexpression in well-differentiated tumors, the
expression levels decreased as the tumors acquired more
malignant characteristics. Poorly differentiated tumors
expressed lower levels of both TMPRSS1 and TMPRSS3.
Notably, both mRNA and protein expression levels were
associated with the clinical characteristics of breast can-
cer: Low expression levels predicted poorer survival and
increased risk of distant metastasis compared to high
Pelkonen et al. BMC Cancer  (2015) 15:431 Page 12 of 15expression levels. Low TMPRSS1 and TMPRSS3 expres-
sion remained independent factors affecting breast cancer-
specific survival in the Cox regression analysis.
These results are consistent with previous studies that
reported TMPRSS1 overexpression in various cancers, es-
pecially in prostate cancer [10–14], as well as TMPRSS3
overexpression in pancreatic and ovarian cancers [16, 17].
We found a notable difference in TMPRSS1 and TMPRSS3
mRNA expression between benign samples and grade I
malignant tumors in that grade I breast cancer samples
expressed considerably higher levels of TMPRSS1 and
TMPRSS3 than benign samples. This finding supports the
theory that hepsin is related to prostate cancer and sug-
gests that hepsin and TMPRSS3 may also play important
roles in the early phases of breast carcinogenesis [32, 33].
Our hepsin and TMPRSS3 immunohistochemical staining
results correlated with the mRNA expression results. Spe-
cifically, samples with more intense cytoplasmic staining
were associated with lower tumor grade and stage, and
samples with low expression levels were linked to grade III
and stage III and IV tumors. Low mRNA expression levels
were common in tumors that did not express hormone re-
ceptors but that were HER2-positive. In addition, hepsin
expression was low in samples with positive nodal status.
In the current study, many of the clinical variables that are
generally related to advanced breast tumor progression
and higher breast cancer mortality rate were linked with
low expression levels of the studied genes [34, 35].
Our survival results indicated that low expression of
both of the studied genes was an independent prognostic
factor in breast cancer. Along with positive nodal status
and large tumor size (T3, T4), low mRNA expression
remained an independent factor for breast cancer survival.
Similarly to our results, Dhanasekaran et al. showed previ-
ously that low hepsin protein expression in human pros-
tate cancer samples correlated with poor prostate cancer
prognosis [36]. In their study, absent or low hepsin im-
munostaining was dominant in benign samples, whereas
hepsin staining was strong in cancer samples. The stron-
gest hepsin staining was in the precursor lesions of pros-
tate cancer (HG-PIN). Yet among cancer samples, absent
or low hepsin expression was associated with prostate-
specific antigen (PSA) elevation after radical prostatec-
tomy and large tumor size, indicating poorer survival. In
contrast, regarding tumor malignancy, high TMPRSS1
mRNA expression correlated with advanced tumor stages
in prostate cancer [37]. Roemer et al. showed that in renal
cell carcinoma, decreased TMPRSS1 mRNA expression
was an independent factor that predicted poorer renal cell
carcinoma-specific survival [38]. They suggested that hep-
sin may be involved in both the early and late develop-
ment of renal cell carcinoma. However, Betsunoh et al.
have observed that hepsin overexpression is associated
with poorer renal cell carcinoma survival [39]. In humanhepatocellular carcinoma, Chen et al. found that de-
creased TMPRSS1 mRNA expression predicted shorter
survival time [40]. These studies illustrate variations
among the different studies; even so, many of these studies
are in agreement with our findings.
In this study we have shown that altered TMPRSS1
and TMPRSS3 expressions are associated with the occur-
rence of relapses and that low TMPRSS3 mRNA and pro-
tein expression are independent factors affecting distant
metastasis occurrence. Aberrant expression of TTSPs is as-
sociated with tumor invasion and metastasis in various epi-
thelial cancers [6, 41]. Supporting our results, Vasioukhin
hypothesized that hepsin may promote metastasis in pros-
tate cancer [32]. This hypothesis suggested that in the
initial stages of metastasis, hepsin overexpression might
stimulate the invasion of primary tumor cells but, once the
cells metastasized, hepsin expression would no longer be
essential in distant lesions. We found that distant metasta-
ses occurred more frequently during follow-up, in patients
with low expression levels of the studied genes in primary
tumors. This finding supports the theory that distant me-
tastases are more likely to occur once a certain stage in
tumor development is reached, and expression of proteo-
lytic serine proteases is needed from primary tumors to
achieve that stage. When local breast cancer relapses and
distant metastasis were studied together, low TMPRSS3
mRNA and protein expression remained independent fac-
tors that affected relapse in the Cox regression analyses.
On the other hand, based on prostate cancer cell line stud-
ies, Srikantan et al. suggested that hepsin overexpression
could have antitumorigenic effects and hinted that hepsin
might be involved in some sort of positive feedback re-
sponse [42]. They suggested that decreased hepsin expres-
sion could be linked with poor prostate cancer prognosis
as exogenously provided hepsin negatively regulated the
growth of metastatic prostate cancer cells. However, the
first hepsin expression study in MDA-MB-231 and HER18
breast cancer cell lines showed that low hepsin expression
levels reduced cell viability and the colony formation rate
[14]. Wittig-Blaich et al. showed in a prostate cancer cell
line study that the consequences of increased hepsin
expression at the cellular level depend on the cell’s micro-
environment, and the authors suggested that hepsin over-
expression must be spatially and temporally restricted for
the efficient development of tumors and metastases [43].
Taken together, these findings support the theory that, de-
pending on the phase of tumorigenesis and metastasis,
hepsin expression might either promote or suppress
tumors and metastasis.
Based on their proteolytic activity at the cell surface,
TTSPs could contribute to tumor progression by affect-
ing initiation of the metastatic process in primary breast
cancer tumors. Several substrates for hepsin have been
linked to epithelial carcinogenesis, including HGF and
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convert inactive pro-HGF to biologically active HGF
that, in turn, activates the HGF receptor c-Met [21, 22].
This leads to basement membrane disorganization. Ab-
normal activation of the HGF/c-Met signaling pathway
by aberrant hepsin overexpression is a possible mechanism
for the enhancement of tumor progression. In addition,
hepsin converts potently pro-uPA into active uPA, which
initiates the degradation of ECM by cleaving plasminogen
into plasmin [23]. Hepsin may also directly contribute to
tumor progression and metastasis by causing defects in cell
junctions. Miao et al. showed in human and mouse ovarian
cancer cell line studies that hepsin overexpression contrib-
utes to ovarian cancer progression via cell membrane inter-
actions with desmosomes [44]. By immunofluorescence
they showed that, in addition to cytoplasm hepsin co-
localizes with desmosomes at the cell junctions; further,
intact desmosomes are required for the membrane lo-
calization of hepsin. Supporting these findings, Partanen
et al. recently reported that hepsin partially co-localizes
with the desmosomal junction protein desmoplakin and,
in breast cancer, the two proteins no longer co-localize
when lkb1 expression is lost [25]. Notably, loss of lkb1
causes hepsin to relocalize from desmosomes to cyto-
plasm. Taken together, these studies indicate that the
mislocalization and overexpression of hepsin could po-
tentially initiate basement membrane degradation and
lead to tumor cell invasion.
The limitations of our study include that TMPRSS3
expression in cancer has not nearly been studied as ex-
tensively as the expression of TMPRSS1. More work
needs to be done to study the biological role of
TMPRSS3 in cancer. Nonetheless, our study presents in
a coherent clinical breast cancer sample set that
TMPRSS3 is a credible prognostic biomarker. In con-
trast to our results, a previous study presented that hep-
sin overexpression was associated with positive nodal
status and tumor stage in breast cancer [14]. However,
no survival analyses were done in that study and the
analysis methods were different. In addition, to validate
our results and the prognostic value of the studied genes
in a large clinical breast cancer microarray database, we
used an online Kaplan-Meier survival analysis tool [31].
Similar to our study, in these analyses the cohorts were
divided into two groups according to the median expres-
sion of TMPRSS1 and TMPRSS3. Based on the survival
curves displayed and the logrank P values both low
TMPRSS1 and TMPRSS3 expression significantly associ-
ated with poorer relapse-free survival, overall survival,
and distant metastasis-free survival [31]. To sum up, the
survival trend was exactly alike compared to our results.
When the treatment data was included in the multi-
variate survival analyses, low TMPRSS1 mRNA expres-
sion remained an independent factor of poor prognosisin patients who were treated with radiotherapy. It must
be highlighted that low TMPRSS1 expression remained
the only significant variable regarding prognosis which
excludes for example poor differentiation level of breast
cancer cells in these analyses. Furthermore, no signifi-
cant results were found in patients who were not given
any adjuvant therapies. When TMPRSS1 expression level
is higher and epithelial integrity is still rather intact it
might be that radiation induced cellular lethality is much
more aggressive in breast cancer cells. However, when
TMPRSS1 expression is low and epithelial integrity already
damaged it appears that the remaining breast cancer cells
are radioresistant leading to these cells surviving which
has negative impact on the clinical outcome. Our results
indicate that low TMPRSS1 expression may independently
reduce the therapeutic function of radiation yet the spe-
cific cellular mechanisms remain unclear. Interestingly,
Nakamura et al. showed in an endometrial cancer cell line
study that hepsin overexpression resulted in significant
cell accumulation at the G2/M phase leading to cell cycle
arrest [45]. Cancer cells in general are thought to be the
most radiotherapy sensitive exactly at the G2/M phase
[46]. These previous studies comply our results even
though our significant results are related to mRNA ex-
pression and in breast cancer tumor samples. In a previ-
ous study of our group we found several TMPRSS1 and
TMPRSS3 SNP genotypes that associated with survival in
patients treated with radiotherapy [26]. We have planned
to study in the future the potential associations between
our current results with the ones from our SNP study.
The combinations of low expression levels of mRNA
and protein were independent factors that predicted
poor survival. This suggests that TTSPs are prognostic
biomarkers for breast cancer. Matriptase (encoded by
the ST14 gene) is a TTSP that, similar to hepsin, can ac-
tivate pro-HGF. A recent study showed that hepsin and
matriptase are direct pericellular activators of pro-HGF
and hypothesized that their suggested ability to autoacti-
vate might be the initial step in HGF/c-Met-mediated
basement membrane degradation [47]. Our previous
study of matriptase expression in breast cancer resulted
in conclusions that were similar to those in the present
study in that low matriptase expression was associated
with poorer breast cancer survival [27]. However, others
have reported the opposite and other studies of matrip-
tase expression in breast cancer have not given consist-
ent results [48]. Notably, since matriptase and hepsin
have identical substrates and since both have possible
tumor progression and metastasis-promoting activities,
further studies of TMPRSS3 are needed to better under-
stand its functions and substrates. Structurally, TMPRSS3
is almost identical to hepsin, and here we have shown that
their mRNA and protein expression patterns are very
similar in different phases of breast carcinogenesis and
Pelkonen et al. BMC Cancer  (2015) 15:431 Page 14 of 15correlate with breast cancer prognosis. Co-expression of
these proteolytic serine proteases could enhance their
effects on tumor cell invasion and metastasis.
Conclusions
In closing, this study expands our knowledge of the bio-
logical processes behind breast cancer by investigating
hepsin and TMPRSS3 expression in human breast tumors.
Low mRNA and protein expression levels of the studied
TTSPs were prognostic markers of poor survival in breast
cancer. Furthermore, low TMPRSS1 mRNA expression is
an independent marker of poor clinical outcome in pa-
tients treated with radiotherapy. We think that our results
give emphasis to the role of altered expression of hepsin
and TMPRSS3 in promoting breast tumor progression
and metastasis as their role in breast cancer is still rather
unexplored. The results showed that both TTSPs have
potential as prognostic biomarkers.
Additional files
Additional file 1: Table S1. Significant clinical variables associated with
hepsin and TMPRSS3 protein expression.
Additional file 2: Figure S1. The studied A, TMPRSS1 and B, TMPRSS3
mRNA expression levels in benign breast tumor samples and in
malignant tumors grouped by tumor grade. In benign tumors, the mRNA
expression levels are lower compared to grade I tumors. Tumor grade is
inversely associated with TMPRSS1 and TMPRSS3 mRNA expression levels.
In grade I tumors, the cancer cells were well differentiated, in grade II
tumors, the cells were moderately differentiated, and in grade III tumors,
the cancer cells were poorly differentiated or undifferentiated. *P < 0.005
mRNA expression in benign tumors versus grade I tumors and grade I
tumors versus grade III tumors.
Additional file 3: Figure S2. Breast cancer relapse-free survival compared
to TMPRSS3 expression levels in Kaplan-Meier survival analysis and in Cox
regression multivariate analysis. Both local and distant recurrences were
taken into account. Patients were divided into high and low expression
groups relative to the median expression values. Low expression levels of A,
TMPRSS3 mRNA (median survival time 7.73 years) and B, TMPRSS3 protein
(median survival time 8.84 years) associated with relapses occurring more
frequently. Low expression levels of C, TMPRSS3 mRNA (median survival
time 9.10 years) and D, TMPRSS3 protein (median survival time 7.66 years)
expression remained independent prognostic factors of more frequent
occurrence of breast cancer relapse. In addition to expression levels, tumor
grade, nodal status, tumor size, ER status, PR status, and histologic type were
included in the multivariate analyses.
Additional file 4: Figure S3. Breast cancer distant metastasis-free
survival in Kaplan-Meier survival analysis. Patients were divided into high
and low expression groups relative to the median expression values. Low
expression levels of A, TMPRSS1 mRNA (median survival time 7.66 years);
B, TMPRSS3 mRNA (median survival time 7.78 years); and C, TMPRSS3
protein (median survival time 9.13 years) associated with distant metastasis
occurring more frequently.
Additional file 5: Table S2. Significant clinical variables associated with
combined TMPRSS1-TMPRSS3 mRNA.
Additional file 6: Figure S4. Breast cancer survival and distant
metastasis-free survival compared to combined mRNA and protein
expression variables in Kaplan-Meier survival analysis. The ‘combined low
expression’ groups of A; C, TMPRSS1 and TMPRSS3 mRNA (A, median
survival time 9.84 years; C, median survival time 7.96 years); and B; D,
hepsin and TMPRSS3 protein (B, median survival time 10.94 years; D,
median survival time 9.13 years) expression associated with poorer breastcancer specific survival (A, B) and with distant metastasis (C, D) occurring
more frequently.
Additional file 7: Figure S5. The prognostic value of low TMPRSS1 and
TMPRSS3 mRNA expression levels in breast cancer was validated in a
public gene expression dataset. The results obtained from the online
Kaplan-Meier plotter analysis tool presented that both low TMPRSS1 and
TMPRSS3 expression were significantly associated with poorer relapse-free
survival (TMPRSS1, A; TMPRSS3, B), overall survival (TMPRSS1, C; TMPRSS3,
D), and distant metastasis-free survival in breast cancer (TMPRSS1, E;
TMPRSS3, F). Patients were divided into high and low expression groups
relative to the median expression values.
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